iRhythm

Also, Japan has approved iRhythm's AI-based continuous ECG monitoring system.

The latest clearance is for an algorithm that characterizes how much atrial fibrillation a patient is experiencing over time.

An algorithm trained on a deep neural network was able to perform on par with board certified cardiologist when annotating 12 different types of heart rhythms. 

iRhythm Technologies reported a promising second quarter from a financial standpoint, citing a revenue of $35.

iRhythm Technologies, maker of the Zio XT and Zio AT adhesive heart monitors, announced first quarter financials boasting higher revenue and an improved gross margin during an earnings call for investors earlier this week.

Patients at increased risk for atrial fibrillation wearing iRhythm’s Zio patch — a  continuous ECG monitoring wearable — were more likely to have their atrial fibrillation diagnosed early and receive subsequent preventive care, according to one-year results from a late-breaking study presented at the American College of Cardiology’s annual meeting.

The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation.

Research firm Tractica predicts that worldwide unit shipments of clinical and non-clinical connected wearable patches will grow to 12.

iRhythm Technologies, maker of the Zio patch peel-and-stick heart monitor, has raised $17 million in a round led by Novo A/S, a Danish life sciences investment firm.